<DOC>
	<DOC>NCT02979431</DOC>
	<brief_summary>The primary objective is to evaluate the anti-viral effect and safety of different doses of inhaled ALX-0171 in subjects hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection (RSV LRTI). The secondary objective is to evaluate the clinical activity, pharmacokinetic (PK) properties, pharmacodynamic (PD) effect and immunogenicity of different doses of inhaled ALX-0171.</brief_summary>
	<brief_title>Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>Subject is otherwise healthy, but is hospitalized for and clinically diagnosed with RSV LRTI Subject has a positive RSV diagnostic test. Symptoms likely related to RSV infection have appeared within 4 days of screening and are not yet improving at screening. Others as defined in the protocol Subject is known to have significant comorbidities Subject is known to be human immunodeficiency virus (HIV)positive Subject is known to be immunocompromised Subject has or is suspected to have an active, clinically relevant concurrent infection Others as defined in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>